Protocols
17 protocol(s) meet the specified criteria
PI: Shea, Thomas
Protocol No.TitleStatus
201312100A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell TransplantOpen
471501A Two-Part, Multi-Center, Prospective, Phase 2/3 Clinical Study to Evaluate the Safety and Efficacy of GLASSIA as an Add-On Biopharmacotherapy to Conventional Steroid Treatment in Subjects with Acute Graft-Versus-Host Disease with Lower Gastrointestinal InvolvementOpen
A221301OLANZAPINE FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALOpen (affiliates only)
BMT-CTN-0702LTContinued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702 Open
BMT-CTN-1101BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic MalignanciesOpen
BMT-CTN-1102A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic SyndromeOpen
BMT-CTN-1202Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCTOpen
BMT-CTN-1301A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host DiseaseOpen
BMT-CTN-1302Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple MyelomaOpen
CALGB10603A Phase III Randomized, Double-Blind Study Of Induction (Daunorubicin/Cytarabine) And Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (Pkc412) (Ind #101261) Or Placebo In Newly Diagnosed Patients < 60 Years Of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)Open (affiliates only)
CALGB50803A Phase II Trial of Lenalidomide (Revlimid™, CC-5013)(NSC #703813, IND #70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL) Open (affiliates only)
CALGB50904A Randomized Phase II Trial of Ofatumumab and Bendamustine Vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma Open (affiliates only)
E1Z11A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)Open (affiliates only)
LCCC1524-ATLPhase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas after High Dose Therapy and Autologous Stem Transplantation (ATLAS)Open
LCCC1532-ATLPhase Ib/II Study of the Administration of T lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s LymphomaOpen
PCYC-1140-IMA Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)Open
S1001A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) Open (affiliates only)